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From analyses of clinical samples, the catalog of muta-
tions has been accruing slowly and inexorably over time.The Bcr-Abl fusion protein kinase causes chronic my-
Kinases are highly plastic structures, existing in equi-eloid leukemia and is targeted by the signal transduc-
librium between conformations that favor catalytic activ-tion inhibitor STI-571/Gleevec/imatinib (STI-571). Se-
ity (the “open,” active state) or catalytic quiescence (thequencing of the BCR-ABL gene in patients who have
“closed,” autoinhibited state; Huse and Kuriyan, 2002).relapsed after STI-571 chemotherapy has revealed a
Point mutation, deletion, or gene fusion can favor consti-limited set of kinase domain mutations that mediate
tutive kinase activation and cell transformation, withdrug resistance. To obtain a more comprehensive sur-
SRC and ABL as classic examples. The specificity ofvey of the amino acid substitutions that confer STI-
kinase inhibitors is tied to the recognition of unique571 resistance, we performed an in vitro screen of
conformations of the kinase domain. The cocrystalrandomly mutagenized BCR-ABL and recovered all of
structure of STI-571 and the ABL kinase domain re-the major mutations previously identified in patients
vealed that the drug achieves specificity by trapping theand numerous others that illuminate novel mecha-
kinase in an ABL-specific inactive conformation throughnisms of acquired drug resistance. Structural model-
an induced fit mechanism (Nagar et al., 2002; Schindlering implies that a novel class of variants acts allosteri-
et al., 2000). Apparently, the inactive, closed conforma-cally to destabilize the autoinhibited conformation of
tion of ABL is not completely destabilized by the fusionthe ABL kinase to which STI-571 preferentially binds.
to BCR and is kinetically accessible to the drug.This screening strategy is a paradigm applicable to a
To date, sequencing efforts to discover drug-resistantgrowing list of target-directed anti-cancer agents and
mutations in BCR-ABL have focused exclusively on theprovides a means of anticipating the drug-resistant
kinase domain. We reasoned that other domains of thisamino acid substitutions that are likely to be clinically
protein important for regulation of kinase activity mightproblematic.
play a role in mechanisms of resistance. Indeed, like the
related c-SRC kinase, c-Abl is regulated by intramolecu-Introduction
lar interactions with domains sharing homology to SRC,
specifically, SRC Homology Domains 3 (SH3) and 2
The era of target-directed cancer chemotherapy has
(SH2), as well as the linker region between the SH2 and
scored a major success with STI-571, a highly specific the catalytic domain (called the SH2-CD linker; Barila
kinase inhibitor that targets the Bcr-Abl oncoprotein and Superti-Furga, 1998). In addition to these intramo-
product of the Philadelphia chromosome in patients with lecular mechanisms of regulation, the SH3 domain of
chronic myeloid leukemia (CML). A deregulated tyrosine c-Abl binds several different cellular proteins that are
kinase, Bcr-Abl can act on its own to induce a CML-like candidates for regulators of c-Abl, notably, Abi-2,
myeloproliferative condition in murine models (Daley et 3BP-1, and Pag/MSP23, the last of which has been
al., 1990; Gishizky et al., 1993; Li et al., 1999). Mutations shown to inhibit c-Abl kinase activity (Cicchetti et al.,
that disrupt kinase activity abrogate all transforming 1995; Dai and Pendergast, 1995; Wen and Van Etten,
functions of Bcr-Abl, a fact that suggested a small mole- 1997). Mutations affecting either intramolecular regula-
cule kinase inhibitor would be a potent anti-leukemic tory interactions or binding of cellular inhibitors might
agent. Indeed, STI-571 induces complete remission in confer drug resistance through novel mechanisms.
virtually all patients with the indolent chronic phase of Given the complexity of ABL kinase regulation and the
CML who are treated immediately upon diagnosis (Kant- limited focus in the clinical literature on kinase domain
arjian et al., 2002). When treated during the more aggres- mutation, we undertook an unbiased, in vitro screen
sive stage of blast crisis, most patients ultimately evolve to identify a more comprehensive set of drug-resistant
drug-resistant disease (Druker et al., 2001; Sawyers et variants than has been cataloged to date in patients.
Our screen identified essentially all of the significant
drug-resistant amino acid substitutions found in pa-*Correspondence: daley@wi.mit.edu
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Figure 1. BCR-ABL Mutagenesis and In Vitro Screen for STI-571 Resistance
The 10 kb plasmid pEYKBA was propagated in XL-1 red (Stratagene), which introduces random point mutations at a rate of one base pair
substitution per 10 kb replicated DNA. Retroviral supernatants with titers of 106 would represent a library approximating saturation mutagenesis
of BCR-ABL. Cells were selected in either 5 or 10 M STI-571, as the numbers of colonies resulting from exposure to lower drug concentrations
(1 and 2 M) were too numerous to analyze and did not afford tight selection of resistant variants.
tients, and predicts a number of additional variants that sequenced the recovered genes to identify mutations
(Figure 1).are likely to be clinically problematic. Furthermore, we
have discovered novel variants that illuminate an impor- From 283 drug-resistant colonies, we identified 112
distinct amino acid substitutions affecting 90 residues.tant functional principle: while STI-571 binds preferen-
tially to the inactive conformation of the ABL kinase, Substitutions at 68% of positions were identified more
than once. Figure 2 depicts a sequence alignment ofdrug-resistant mutations can shift the equilibrium in the
opposite direction, further destabilizing and activating ABL with the closely related cytoplasmic tyrosine ki-
nases SRC and HCK as well as the receptor kinases KITthe kinase, and rendering the inactive conformation less
accessible for drug binding. Our screen is a paradigm and platelet-derived growth factor receptor (PDGF-R),
both of which are also targets of STI-571. The variantsfor discovery of drug-resistance mechanisms for a grow-
ing list of target-directed anti-cancer agents. recovered in the screen are indicated, as are the salient
secondary structural motifs and functional domains of
ABL. To verify the activity of variants in isolation (sinceResults
some recovered viruses carried two or more mutations)
we generated 65 variants by site-directed mutagenesisAn In Vitro Screen for Drug-Resistant Variants
We constructed pEYKBA by introducing the full-length of the native BCR-ABL sequence. We reintroduced
these into BaF3 cells, and measured cell viability in in-BCR-ABL cDNA into pEYK3.1, a retroviral vector de-
signed to facilitate expression screens by allowing direct creasing doses of drug to document the concentration
that provided half-maximal inhibition of cell viabilityrecovery of integrated proviruses from genomic DNA of
infected cells (Koh et al., 2002). We randomly mutagen- (IC50; Tables 1 and 2). We also performed phosphotyro-
sine immunoblot analysis on protein lysates of BaF3ized the BCR-ABL plasmid by propagation in a bacterial
strain that is deficient in three major pathways for DNA cells incubated with increasing doses of STI-571 (Figure
3). The vast majority of the variants we regenerated byrepair (XL-1 red; Stratagene). We transfected the mutant
plasmids onto 293T cells, recovered retroviral superna- site-directed mutagenesis showed enhanced cell growth
(elevated IC50) and persistent autophosphorylation intants, transduced the transformation-susceptible in-
terleukin 3-dependent hematopoietic cell line BaF3 (Da- the presence of STI-571 and, thus, were confirmed to
be drug resistant (59 of 65; 91%). We failed to replicateley and Baltimore, 1988), and selected for colony growth
in soft agar in the absence of IL-3 and the presence drug resistance for six variants, establishing a modest
9% false positive rate for the screen.of either 5 or 10 M STI-571. Under these conditions,
colonies arise only from cells carrying BCR-ABL cDNAs In this manuscript, we number the amino acid residues
in our figures according to the human c-Abl type Ibthat express transformation-competent and drug-resis-
tant variants. After 10 days, we plucked well-separated sequence, rather than type Ia, which was the custom
arbitrarily adopted by Kuriyan and colleagues in the orig-individual colonies, which varied in size, and expanded
them in liquid culture. We then isolated genomic DNA inal report of the ABL kinase domain structure (Schindler
et al., 2000). Type Ia numbering has been perpetuatedand recovered the integrated provirus by direct rescue,
as described (Koh et al., 2002), or amplified specific in recent reports describing drug-resistant mutations
arising in patients. However, type Ib is the major formregions of the ABL gene sequence by PCR. We then
STI-571/Gleevec/Imatinib Resistance of Bcr-Abl
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Figure 2. ABL Mutations and Their Homologous Positions within Four Conserved Kinases
ABL, c-SRC, c-HCK, c-KIT, and the PDGF receptor sequences were aligned and labeled for functional domains. The ABL secondary structure
was also annotated. Helices are represented as cylinders and  sheets are shown as boxes with arrows. Each mutation identified in this study
is highlighted with an arrow above the corresponding sequence position along with the substitutions that were isolated. An asterisk indicates
the position of the auto-regulatory phosphorylation site within the activation loop (Y412).
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Table 1. Mutations in the Kinase Domain
, independent isolate. IC50 as measured in transformed BaF3 cells. ND, not determined. IC50 for native Bcr-Abl is 0.6 M STI571. Shaded
variants have been reported in patients. Structural motifs and critical SH3, SH2 contacts with the kinase domain are indicated on the left side
of table.
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Figure 3. Immunoblot Analysis of BaF3 Cells Transformed by STI-571 Resistant Variants and Exposed to Varying Doses of STI-571
(A) Cap region, SH3, SH2, and SH2-CD linker domain variants, and (B) kinase domain variants. Anti-Yp, immunoblot with anti-phosphotyrosine
antibody; Anti-ABL, immunoblot with anti-ABL antibody. Native BaF3 cells transformed by native Bcr-Abl protein. Doses are indicated. The
variants V275A and M337A generated by site-directed mutagenesis did not specify drug-resistant autophosphorylation. Certain variants
recovered in the screen also did not generate drug-resistant autophosphorylation levels significantly greater than native Bcr-Abl (V224E,
A385D, G482D) and thus were judged to be false positives. Numbering of residues according to type Ia c-Abl is shown in parentheses for
substitutions previously linked to drug resistance in patients.
of c-Abl expressed in cells, and the description of its adoption of the type Ib numbering system in this and
future publications. In Tables 1, 2, and 3, we have labeledcrystal structure (Nagar et al., 2003 [this issue of Cell]),
which has important implications for understanding the mutations according to both the type Ib and Ia number-
ing systems to enable convenient translation.mechanism of STI-571/imatinib resistance, warrants
Cell
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Figure 4. Mapping of Mutations to Structural Models of ABL
(A) Two opposite views of the ABL kinase domain solvent accessible surface, encompassing amino acid residues 76–517 (57–498 by type Ia
numbering, PDB 1IEP; Nagar et al., 2002). Labeled and highlighted in blue or red are the positions of kinase domain mutations isolated in
this study. Internal residues that are not exposed on the surface of the protein are not depicted. Mutated residues that mediate contacts with
either SH3 or SH2 are colored red. (B) Two opposite views of the predicted surface of a composite ABL kinase (PDB 1IEP; Nagar et al., 2002),
SH3/SH2 (PDB 2ABL; Nam et al., 1996), and CD-linker model. The two perspectives of the composite ABL SH3/SH2/kinase model are colored
as in (A). The SH3 domain is shown in green, the SH2 domain in cyan, and the CD linker in white. (C) Ribbon depiction of SRC structure
alignment with ABL model. SRC (PDB 1FMK; Xu et al., 1997) is shown in yellow, ABL in white. Variants identified in this screen are colored
as in (A). Potential complimentary mutations are labeled according to their relative positions within the model.
STI-571/Gleevec/Imatinib Resistance of Bcr-Abl
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Kinase Domain Variants interaction in c-Abl, resulting in autophosphorylation
and transforming activity. Mutation of the Q327 residueThe variant residues reported to date in patients cluster
within specific functional regions of the kinase domain, of c-SRC, which is homologous to Q319 of ABL, similarly
disrupts SRC kinase regulation (Gonfloni et al., 1997).notably the drug binding cleft and phosphate binding P
loop, and the activation loop (Shah et al., 2002). We When expressed in BaF3 cells, the STI-571-resistant
Q319H variant has elevated baseline levels of tyrosineisolated each of these major patient variants in our
screen, as well as additional residues mapping within autophosphorylation, which is evident even though Bcr-
Abl already shows markedly elevated levels of auto-these same functional motifs, suggesting that our
screen was more comprehensive than the compiled data phosphorylation relative to c-Abl (Figure 3B). Mutation in
these residues implies that alteration of SH3 associationfrom analysis of clinical samples (Table 1). For example,
L267R/V are novel P loop variants that confer high-grade with the small N lobe of the Bcr-Abl kinase deregulates
the enzyme in a manner associated with drug resistance.resistance in cell-based assays (R  20 M; V  9.8
M; Table 1) but have not yet been reported in patients. SH2 is important for binding phosphotyrosine-con-
taining peptides, enhancing phosphorylation of specificGiven that the other P loop variants confer a similar
degree of resistance, L267 variants are likely to be found substrates and positively modulating Bcr-Abl transfor-
mation activity (Mayer and Baltimore, 1994; Pendergastonce additional patients are surveyed. We identified
three novel drug-resistant variants within the activation et al., 1991). By homology to c-SRC, the kinase domain
interface with SH2 is made by part of the long 3 helixloop (L403M, M407I, and G417R) in addition to substitu-
tions at two residues already reported in patients: within the large C lobe, which includes the variants
M362T (M343T-Ia) and M370T/I (M351T/I-Ia) already re-V398E/A (V379I-Ia), H415R/P (H396R-Ia; Shah et al.,
2002). Moreover, we discovered numerous novel kinase ported in patients (Shah et al., 2002) and the novel vari-
ants V357G, V358A/G, A363V, Q365H, and E371K identi-domain variants outside of the drug binding cleft and
activation loop, clustering in the conserved VAVK of the fied in our screen. In particular, the side chains of
residues V357, V358, Q365, and E371 would be pre-kinase 3 sheet, the catalytic 1 helix of the small N
lobe, the long 3 helix within the large C lobe, and the dicted to face SH2 and, therefore, may partially deter-
mine the specificity of contacts along this surface (Fig-region within the C lobe downstream of the activation
loop (Figure 2; Table 1). ure 4A, left). SRC-homologous residues that are
significantly distal to the active site are also likely toWe colored the locations of variant amino acid resi-
dues on a rendered molecular surface of the ABL kinase make contact with SH2, notably E513, E518, I521, and
E528 (N.B., 517 is the last residue in the available ABLdomain and noted several prominent clusters that coin-
cide with critical functional regions (Figure 4A). One clus- crystal structure and thus our model). Substitution at
these residues might influence drug resistance by dis-ter surrounding the ATP/drug binding cleft dominates
the small N lobe of the kinase domain (Figure 4A, right). rupting the SH2 association with the kinase domain or
because of distortions in the C lobe of the kinase itself.Since all variants retain transforming activity, these must
alter the charge, shape, and/or deformability of the con-
tact surface of the active site in a manner that modifies Variants Outside the Kinase Domain:
drug affinity while retaining ATP binding and catalytic The Cap Region
function. Several variants are evident in the activation Given that we detected clusters of kinase domain muta-
loop that would potentially destabilize the inactive loop tions that implied the importance of contacts with the
conformation, which is a critical prerequisite of STI-571 regulatory SH3 and SH2 domains, we sought to identify
binding (Figure 4A, right). variants in complementary binding surfaces of SH3 and
SH2 and to determine whether regions outside the ki-
nase domain might contribute to drug resistance. Thus,Unanticipated Resistance Mechanisms
Perhaps most interesting, however: mapping the large we sequenced more extensively those plasmids recov-
ered from drug-resistant cells that had yielded no muta-number of variants identified in our screen to the ABL
kinase structure reveals clusters in distinct regions that tions within the kinase domain and, indeed, discovered
additional variants. Starting from the most N-terminalimply novel mechanisms of drug resistance. On the op-
posite face of the kinase domain from the nucleotide/ ABL sequences preserved within the Bcr-Abl fusion, we
identified several substitutions within the “cap” regiondrug binding site, two clusters occur in amino acid resi-
dues that are homologous to residues in SRC and HCK that has been implicated in the autoinhibition of c-Abl
(Pluk et al., 2002). This cap is believed to stabilize theknown to make contact with the regulatory SH3 and
SH2 domains (Figure 4A, left; Gonfloni et al., 1999, 2000; kinase in the inactive conformation, analogous to the
role of the C-terminal tether region of c-SRC that con-Xu et al., 1999, 1997). SH3 negatively regulates the ABL
kinase. The SRC-homologous SH3 contact surface in- tains the autoinhibitory Y527 residue. Mutation of the
N-terminal cap of c-Abl relieves autoinhibition and acti-cludes K313, Q319, L320, and E335, and variants were
recovered in each of these residues. Previous site- vates autophosphorylation (Pluk et al., 2002). While the
viral oncoprotein v-ABL lacks all of this cap domain, thedirected mutagenesis had linked these contacts to ABL
kinase domain regulation, implying that the K313 residue second ABL exon to which BCR fuses preserves part
of this cap structure, suggesting that Bcr-Abl might beof the putative SH3 contact surface makes a critical salt
bridge to E117 of the SH3 domain, while Q319 links the further deregulated by mutation of the residual cap func-
tion. We discovered a cluster of variants within the capkinase domain and SH3 through interactions with the
SH2-CD linker (Barila and Superti-Furga, 1998). Muta- 6 region (K70Q, E71K, N72D/T; Pluk et al., 2002) and
adjacent residues (A75V, G76E, P77R, and E79K),tions in K313 and Q319 disrupt the SH3-kinase domain
Cell
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Table 2. Mutations Outside the Kinase Domain
, independent isolate. IC50 as measured in transformed BaF3 cells. ND, not determined. IC50 for native Bcr-Abl is 0.6 M STI571. Structural
domains are indicated at the left side of table.
thereby linking cap region mutations to drug resistance. ably contact SH3 and the SH2-CD linker, respectively,
were also shown to destabilize the c-Abl kinase (BarilaThe structure of the N-terminal cap region of ABL is
unknown and, thus, is not depicted in Figure 4. and Superti-Furga, 1998). Again, our study links amino
acid substitutions at these two residues to drug resis-
tance. Thus, our random, unbiased screen for drug resis-Variants Affecting the SH3-Kinase
tance identifies many of the same residues that haveDomain Interaction
been implicated by site-directed mutagenesis in theThe SRC family of kinases is maintained in an assem-
maintenance of ABL in an assembled and presumablybled, autoinhibited conformation in part by intramolecu-
autoinhibited conformation, suggesting that allostericlar interactions between the SH3 domain, the SH2-CD
regulation of kinase activity is intimately tied to druglinker, and the catalytic domain (Xu et al., 1999). Evi-
resistance.dence from site-directed mutagenesis suggests that the
ABL kinase is regulated by a similar set of interactions,
as mutants in each of these three domains activate c-Abl A Model of Autoinhibited ABL
Prior to the report by Kuriyan and colleagues in thiskinase activity and transforming function (Barila and Su-
perti-Furga, 1998). The SH2-CD linkers of SRC and ABL issue of Cell (Nagar et al., 2003), the combined SH3/SH2
and kinase regions of c-Abl had yet to be crystallized asare poorly conserved except for a lysine-proline motif
known to interact with SH3 in SRC. It has been shown a unit, and the structure of the SH2-CD-linker domain
of ABL had not been defined. However, given the strongpreviously that mutation of the KP residues (K241E/
P242G) or mutation of two prolines within the ABL SH2- homologies between ABL and SRC, whose crystal struc-
ture is known, and our evidence that drug-resistant mu-CD linker (P242E/P249E) activates autophosphorylation
and transformation (Barila and Superti-Furga, 1998). Our tations in ABL involve residues homologous to ones that
make critical interdomain contacts in SRC, we built ascreen for drug resistance recovered a remarkably simi-
lar set of mutations, including the T243A variant, which model for the presumptive autoinhibited form of ABL
(Figure 4B). Treating the crystal structures of the ABLis immediately adjacent to P242, and a substitution at
position P249. As discussed above, mutation of the ki- SH3, SH2, and kinase regions as isolated domains, we
aligned the domains relative to one another so that mu-nase domain residues K313 and Q319, which presum-
STI-571/Gleevec/Imatinib Resistance of Bcr-Abl
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tated residues in ABL coincided with their homologous
Table 3. Mutations in STI571 Contact Sitesresidues in SRC. The backbone trace of the presumptive
ABL model was easily aligned to the fully-assembled
SRC structure without any major inconsistencies or dis-
ruptions (Figure 4C). In our model, Y89 contacts the
linker residue K238, while linker position T243 packs
against Q319, exemplifying the linker’s role in bridging
the gap between SH3 and the kinase domain (Figure
4B, right). Mutation of each of these residues confers
drug resistance (N.B., variants Y89D/H/N, K238E,
T243A, Q319H; Table 1 and Table 2), suggesting that
these complementary contacts are critical for main-
taining the assembled conformation of ABL. Some of
the residues highlighted red in Figure 4A as presumptive
contacts with the SH3 and SH2 domains are hidden in
the reassembled molecules (e.g., L320, Q365; Figure
4B). Other residues that are not visible on the surface
projections may be involved in positioning residues that
do directly contact these domains.
Given the relative ease with which our assembled ABL
model conforms to the known crystal structure of SRC,
we conclude that the ABL kinase must be maintained
IC50 for native Bcr-Abl is 0.6M STI571. ND, not determined. Shadedin a similar closed, autoinhibited conformation subject to variants have been reported in patients.
comparable allosteric mechanisms of kinase regulation.
The fact that our drug-resistant variants involve residues
ever, such deregulated variants have enhanced auto-that are homologous to critical interdomain contact sites
phosphorylation activity in cells, which favors adoptionin SRC and involve residues previously shown by muta-
of the catalytically active kinase conformation that pre-genesis to be critical for c-Abl regulation lends support
cludes STI-571 binding.to our model. Indeed, the principle features of our model
Within the connector region between the SH3 andconform closely to the structure for the assembled form
SH2 domains sits V138G and S140R (Figure 4B, left).of type Ib ABL reported by Kuriyan and colleagues in
Point mutation at S140 is activating in c-Abl (Brasherthis issue (Nagar et al., 2003).
et al., 2001), and substitutions at connector residues
between the SH3 and SH2 domains are likewise stronglyOther Variants in SH3 and SH2
activating in c-SRC. Molecular dynamic studies of SRCIn the negative regulatory SH3 domain, we identified a
demonstrate that the connector region holds the SH3cluster of mutations within the highly conserved FVALYD
and SH2 domains together as a rigid unit that acts asmotif. Our model predicts that Y89D/H/N and D90N are
an inhibitory clamp when tethered to the backside ofclosely opposed to the SH2-CD linker domain, while
the kinase (Young et al., 2001). Our screen ties substitu-
V86G and A87E/V are juxtaposed to the SH2 domain
tions at the homologous connector residues to STI-571
(Table 2; Figure 4B, right). A second cluster of SH3 muta-
resistance of Bcr-Abl.
tions involves the WVPS motif between the d and e The SH2 domain is relatively devoid of mutation in
sheets (Figure 2). Among these variants is W129C, which our screen, consistent with its requirement for Bcr-Abl
involves a residue critical for binding of polyproline pep- transformation (Pendergast et al., 1991). Regeneration
tides of the ABL type (Panni et al., 2002). Mutation of of variants at S167, S176, and V224 by site-directed
P131 has been shown to activate c-Abl transformation mutagenesis failed to generate significant drug resis-
activity, to induce relocalization of c-Abl from the nu- tance in liquid culture and, thus, these residues are likely
cleus to the cytoplasm, and to disrupt association with false positives. However, S206F/P is a particularly inter-
Pag/MSP23, a cellular inhibitor of c-Abl (Brasher et al., esting variant. It was isolated twice and confirmed as
2001; Van Etten et al., 1995). P131 is a particularly inter- drug resistant when regenerated in isolation by site-
esting residue with regard to STI-571 resistance. Van directed mutagenesis. S206 is homologous to T218 in
Etten and colleagues have shown previously that when c-SRC, which is found within the specificity determining
assayed by immune complex kinase assay, P131 vari- region of the EF loop of the SH2 domain. Mutation of
ants of c-Abl manifest increased drug resistance. How- T218 or surrounding residues activates c-SRC through
ever, when the c-Abl protein is purified and assayed in loss of association with the C-terminal pY527-con-
its unphosphorylated state, a P131L mutation renders taining c-SRC peptide (Bradshaw et al., 2000). Our isola-
the kinase more sensitive rather than more resistant to tion of an ABL gene mutation in the residue homologous
STI-571 (Roumiantsev et al., 2002). This phenomenom to c-SRC T218 suggests that a critical, yet undefined
is also observed when unphosphorylated c-Abl is dereg- intramolecular interaction or, perhaps, a protein-protein
ulated allosterically by a phosphopeptide ligand (see association, plays a role in regulating ABL.
Figure 6 in Hantschel et al., 2003 [Cell, this issue]). These
data suggest that unfolding of the assembled form of Mutagenesis of Residues that Contact STI-571
ABL may actually enhance drug accessibility to the ac- The cocrystal structures of STI-571 bound to ABL identi-
fied a number of critical contact residues within thetive site of the purified unphosphorylated enzyme. How-
Cell
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active site/drug binding cleft involved in hydrogen bond- We consider these to be false positives in our screen,
random mutants that ride “piggy-back” on true resis-ing or van der Waals contacts (Nagar et al., 2002; Schind-
ler et al., 2000). Variants in contact residues Y272 (Y253- tance mutations missed by our sequencing efforts. Curi-
ously, however, though failing to manifest enhancedIa), T334 (T315-Ia), and F336 (F317-Ia) have been de-
scribed in patients and in our screen, while our screen drug resistance, some of these mutants show persistent
levels of tyrosine autophosphorylation at high doses ofrevealed multiple additional variants in contact residues
(L267R/V, A288V, M309L/T, G340W, and I379F). In order STI-571 (e.g., S176T, A236G; Figure 3A). This biochemi-
cal resistance suggests these might be weak cooperat-to understand why some residues known to contact the
drug remained invariant in our screen, we performed ing mutations whose modest effects might not be re-
solved in short-term cell proliferation assays. Wesite-directed mutagenesis and measured the effects on
kinase activity and drug resistance (Table 3). Contact acknowledge that many of the mutations identified
herein may never be seen in patients but be peculiar toresidue variants V275A and M337A were active kinases,
but their STI-571 resistance profile was indistinguish- our screen, since transformation of BaF3 cells is more
permissive than leukemia induction, and the majority ofable from native Bcr-Abl (Figure 3B). The peptide back-
bone and not the amino acid side chain of M337 medi- novel mutations exert modest effects on drug resis-
tance. Finally, while our screen was exhaustive, it wasates the drug contact for this residue, which explains
why amino acid substitution might not negatively affect not complete. We could productively sequence more
clones to detect additional mutations within the regula-drug binding. Mutation of I332, F401, and the highly
conserved ion pair K290 and E305 resulted in inactive tory domains and extend our survey to include the large
C-terminal domain of ABL as well as BCR sequences.kinases (Table III; kinase inactive substitutions of I322
and E305 confirm a previous report; Corbin et al., 2002).
Thus, mutation of some residues within the active site/ Discussion
drug binding cleft of the ABL kinase results in loss of
enzyme function. We have performed an in vitro screen of mutagenized
BCR-ABL to identify amino acid substitutions that con-
Mutations Predicted to Be Clinically Problematic fer resistance to STI-571. Our results reveal a more com-
As determined in cell-based assays, the IC50 for the prehensive catalog of potential drug-resistant mutations
mutants correlates roughly with the frequency of recov- than provided by clinical surveys to date and illuminate
ery in our screen (Table 1). The robust P loop variants novel mechanisms by which alterations in the ABL struc-
are detected most frequently, a correlation also noted in ture thwart drug efficacy. In addition to all major muta-
clinical populations (Branford et al., 2002). As discussed tions detected in patients, we identified novel substitu-
above, variants at L267 (L248-Ia) are certain to be found tions of residues within and beyond the kinase domain
in relapsed or refractory CML patients. No mutants in that influence the conformational state of the kinase and
the catalytic  helix have been reported to date from confer drug resistance through allosteric mechanisms.
patients, but given their significant degree of drug resis- An important principle to emerge from our in vitro screen
tance, such mutations will likely be discovered when and subsequent structural modeling is that numerous
additional patients are surveyed (e.g., E298K, E300K). drug-resistant variants destabilize an autoinhibited con-
We predict that P249L, L403M, E469K, F505S, and formation of the ABL kinase to which STI-571 preferen-
E518K/I are also likely to be clinically problematic. Muta- tially binds, shifting the equilibrium toward the active
tions in the SH3 domain and S206F/P in SH2 generate kinase conformation that precludes drug binding. Our
only low-level drug resistance (IC50 1 M). Escalating results lend support to the hypothesis that ABL is sub-
the treatment dose of STI-571 should be sufficient to ject to a similar mechanism of autoinhibition as c-SRC
suppress these variants, suggesting that these may be (Barila and Superti-Furga, 1998; Pluk et al., 2002). The
observed only rarely in CML patients, if at all. structure for autoinhibited c-Abl reported by Kuriyan
and colleagues provides confirmation of this hypothesis
(Nagar et al., 2003).Limitations of Our Screen
Our in vitro screen has identified 13 of the 16 drug- Structural and functional data on ABL autoinhibition
reported in the accompanying papers (Hantschel et al.,resistant mutations reported in patients, including all of
those isolated from multiple patients and verified 2003; Nagar et al., 2003) provide a rationale for the mech-
anism of many of the novel drug-resistant variants re-through in vitro analysis (Table 1). We have not recov-
ered E374G (E355G-Ia), F401L (F382L-Ia), and L406M covered in our screen while also raising important ques-
tions for the future. Though the reported structure(L387M-Ia). These first two examples were discovered
in patients as a second site mutation together with a cannot resolve the contact sites of the cap peptide as
it courses over the SH3 and SH2 domains, we havemutation known to confer resistance and have not yet
been observed in isolation (Shah et al., 2002). In our isolated drug-resistant mutants along this stretch, par-
ticularly at residue K70, that imply the importance ofhands, the F401A (F382-Ia) mutation produces an inac-
tive kinase, likely by disrupting the Mg2 binding triad such contacts and beg for further structure refinement.
Molecular dynamic studies of ABL suggest that the con-(Table 3). L406M (L387M-Ia) was reported in a single
patient and has not been independently validated (Shah nector residues between SH3 and SH2 maintain the rigid
positioning of the domains relative to one another, whichet al., 2002). Our screen identified a number of mutants
that when reproduced in isolation by site-directed muta- provides a “clamp” on the kinase domain, as in SRC
(Nagar et al., 2003). A triple glycine mutant in the connec-genesis failed to manifest significant drug-resistance
(e.g., S167C, S176T, V224E, A236G, A385D, and G482D). tor residues between SH3 and SH2 activates c-Abl ki-
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nase activity and autophosphorylation (Hantschel et al., the other known targets of STI-571, or by screening for
2003). Our screen links mutations in these residues to mutations that confer resistance to structurally distinct
drug resistance, likely by weakening the clamp. The classes of kinase inhibitors. As numerous target-directed
autoinhibited conformation of ABL appears to depend signal transduction inhibitors have now entered clinical
upon the docking of the SH2 domain with the large C trials (Shawver et al., 2002), our in vitro screening strat-
lobe of the kinase and that SH2 association and accessi- egy is a paradigm that can be extended to other targets
bility are regulated by myristate binding and phospho- and exploited to predict the mutations that are likely
peptide ligands, respectively. The Bcr-Abl protein has to be clinically problematic. Identification of the most
no myristate and the BCR domain is known to interact refractory drug-resistant variants can serve to inform
directly with SH2 in a non-phosphotyrosine-dependent development of next generation target-directed com-
manner (Pendergast et al., 1991), which may account in pounds.
part for the deregulation of the native Bcr-Abl kinase.
Our screen has identified numerous mutants in the 3/C Experimental Procedures
and 9/I helices of the C lobe, but it is unclear whether
BCR-ABL Mutagenesis, Library Generation, and Screeningthese would further disrupt SH2 association or alter drug
The BCR-ABL cDNA was cloned into the EcoRI site of the pEYK3.1affinity by distorting the C lobe itself. Finally, refinement
retroviral vector (Koh et al., 2002) to generate pEYKBA. One micro-
in the structure of the SH3 domain interaction with the gram of DNA was used to transform the E. coli strain XL-1 red
SH2-CD linker is needed to explain how drug-resistant (Stratagene). The transformants were selected on Zeomycin-agar
variants in this region disrupt the negative regulation of bacterial plates. After 18 hr, colonies were collected by scraping
and the plasmid DNA was isolated. Five micrograms of the plasmidthe kinase. Given the complex effects of mutation on
library were transfected onto HEK 293T cells, and supernatants werethe conformation of the regulatory and kinase domains,
isolated with titers of 105–106 infectious units/ml and used to infectmutations might increase drug resistance by altering
one million BaF3 cells as described (Koh et al., 2002). The cells were
directly the conformation of the ATP binding cleft and/ incubated another 16 hr, then washed with RPMI containing 10%
or by shifting the equilibrium of the kinase to the phos- FCS. 0.5 million cells were plated onto 60 mm dish in RPMI media
phorylated state in cells. Careful enzymatic analysis will supplemented with 20% v/v FCS, 5–10 M STI-571/imatinib (No-
vartis), and 1.2% Bacto-agar. After 10 days, single isolated coloniesbe needed to define how each variant influences drug
were plucked and amplified in liquid culture in the presence of STI-affinity and kinase regulation.
571. Genomic DNA from IL-3-independent and STI-571-resistantIt has been suggested that certain mutations create
cells was isolated. Integrated provirus was recovered as describeda more potent BCR-ABL oncogene and may therefore
(Koh et al., 2002). Alternatively, specific subregions of the BCR-
accelerate disease progression (Roumiantsev et al., ABL cDNA were recovered by PCR amplification with the following
2002). A subset of the mutants we identified appear primers: SH3-SH2 domain, (Bcr-Abl1[5-CTCCACACTGTCCACAG
to hyper-activate autophosphorylation of the Bcr-Abl CATTCC-3]; BAKR1, [5-CTGTCATCAACCTGCTCAGGC-3]); SH2-
kinase domain, (BAKF1 [5- CGTGAGAGTGAGAGCAGTCC-3]; andkinase (e.g., D90N, W129C, E301D, Q319H, F330L, and
BAKR2, [5-GCAGCTCTCCTGGAGGTCCTCG-3]). The rescuedG340W; Figure 3). Moreover, mutation of several of the
plasmids and amplified PCR products were sequenced. Sequenceresidues we have linked to drug resistance have pre-
alignment and analysis was performed by DNASTAR II.
viously been shown to convert c-Abl to an oncogene
(e.g., P131, S140, and Q319; Barila and Superti-Furga,
Plasmid Constructs
1998; Brasher et al., 2001; Roumiantsev et al., 2002; Van Oligonucleotides overlapping the various point mutations identified
Etten et al., 1995). The emergence of specific drug- in the library screen were synthesized by Invitrogen, Inc and used
resistant variants correlates with accelerated disease to perform site-directed mutagenesis on the pEYKBA template
(Quickchange mutagenesis kit; Stratagene). Each mutant was con-progression in CML patients (Shah et al., 2002), and
firmed by sequencing. The numbering of amino acid residues in thisthus, a well-characterized catalog of drug-resistant vari-
paper is according to the type Ib human c-Abl sequence (Fainsteinants will help inform patient prognosis.
et al., 1989). Inconsistency with the numbering schemes of otherMultiple ABL kinase inhibitors will be needed in order
publications results from the alternative 5 exons of the c-Abl gene.
to treat resistant patients, and drugs with activity against Publications that employ numbering according to the type Ia human
the most STI-571-resistant variants should be devel- sequence (Fainstein et al., 1989) differ by 19 amino acid residues.
oped and will be important adjuncts to clinical care We have listed both the Ib and Ia residue numbers in our text when
it appeared helpful.(Shawver et al., 2002; Wisniewski et al., 2002). Given
the mutations defined herein, an appealing strategy for
Cell Viability Assay to Determine IC50suppressing resistance is to treat patients with a combi-
0.5–1 	 104 BaF3 cells expressing mutant Bcr-Abl proteins werenation of STI-571/Gleevec/imatinib and a kinase inhibi-
plated in each well of 96-well plates in RPMI medium containingtor that effectively binds to the active conformation,
10% FCS and lacking IL-3. STI-571 was included in the media in
like PD173955 (Nagar et al., 2002), or alternatively, to increasing concentrations (final concentration: 0, 1, 3, 5, 10, and 20
combine kinase inhibition with dual blockade of a signal- M). Viable cell number was assessed 60 hr later using the WST-1
ing pathway activated by Bcr-Abl, like RAS (Hoover et reagent (Roche), according to manufacturers specifications. Assays
were performed in quadruplicate. A450 readings were averaged andal., 2002). Indeed, more effective target-directed drug
plotted versus concentration of STI-571 as a best fit sigmoidal curvetherapy for CML may need to mimic strategies shown
by using a nonlinear curve-fitting algorithm (Origin 7.0, Origin Lab,effective for HIV, in which multiple protease and reverse
Northampton, MA). The concentration of drug resulting in 50% maxi-transcriptase inhibitors are employed to thwart the drug
mal inhibition is reported as Cellular IC50.
resistance that emerges as the virus rapidly mutates
(Emini, 1995). Immunoblotting
We anticipate that important functional principles 6 	 106 BaF3 cells harboring Bcr-Abl variants were plated in 12 mls
might be discovered by performing a similar screen RPMI medium containing increasing concentration of STI-571 and
incubated for 4–6 hr at 37
C. Cells were collected by centrifugation,against the c-Kit and PDGF receptor tyrosine kinases,
Cell
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washed with PBS, and lysed in 20 mM Tris-Cl (pH 7.5), 50 mM NaCl, for Rac and inhibits growth factor-induced membrane ruffling in
fibroblasts. EMBO J. 14, 3127–3135.1% NP-40, 0.1% SDS, 5 mM EDTA, 1mM EGTA, 1 mM sodium
fluoride, 2 mM Sodium Vanadate, and 5% Glycerol supplemented Corbin, A.S., Buchdunger, E., Pascal, F., and Druker, B.J. (2002).
with protease inhibitor cocktail (Roche) and 1 mM phenylmethylsul- Analysis of the structural basis of specificity of inhibition of the Abl
fonyl fluoride (PMSF). The cell suspension were sonicated for 1 min kinase by STI571. J. Biol. Chem. 277, 32214–32219.
followed by addition of 5	 gel loading buffer (350 mM Tris-HCl [pH
Dai, Z., and Pendergast, A.M. (1995). Abi-2, a novel SH3-containing
6.8], 500 mM DTT, 15% SDS, 10 mM Benzamidine, 5 mM EDTA, 5
protein interacts with the c-Abl tyrosine kinase and modulates c-Abl
mM EGTA, 5 mM Sodium Vanadate, Protease cocktail, 50% Glyc-
transforming activity. Genes Dev. 9, 2569–2582.
erol, and 0.001% Bromophenol blue) and denaturation at 70
C for
Daley, G.Q., and Baltimore, D. (1988). Transformation of an interleu-5–10 min. Proteins were resolved by 7% SDS polyacrylamide gel
kin 3-dependent hematopoietic cell line by the chronic myelogenouselectrophoresis (BIORAD) under denaturing conditions. Immu-
leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USAnoblotting was performed first with the mouse monoclonal anti-
85, 9312–9316.phosphotyrosine antibody 4G10 (Upstate Biotechnology). Blots
Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction ofwere then stripped and reprobed with a rabbit polyclonal anti-ABL
chronic myelogenous leukemia in mice by the P210bcr/abl gene ofantibody (Santa Cruz Biotechnology). Bands were visualized using
the Philadelphia chromosome. Science 247, 824–830.ECL reagents (Pierce) according to the supplier’s recommendation.
Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F.,
Sequence Alignments and Annotation Ford, J.M., Capdeville, R., and Talpaz, M. (2001). Activity of a specific
Sequences were aligned with ClustalX v1.81 (Thompson et al., 1997), inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic
using the Gonnet series weight matrix. Both pairwise gap opening myeloid leukemia and acute lymphoblastic leukemia with the Phila-
and gap extension penalties were set at 10.00 and 0.10, respectively. delphia chromosome. N. Engl. J. Med. 344, 1038–1042.
Multiple alignment gap opening and gap extension penalties were Emini, E.A. (1995). Resistance to anti-human immunodeficiency vi-
set at 10.00 and 0.20. The secondary structural folds were deter- rus therapeutic agents. Adv. Exp. Med. Biol. 390, 187–195.
mined according to PDB 2ABL (Nam et al., 1996) and PDB 1IEP
Fainstein, E., Einat, M., Gokkel, E., Marcelle, C., Croce, C.M., Gale,(Nagar et al., 2002).
R.P., and Canaani, E. (1989). Nucleotide sequence analysis of human
abl and bcr-abl cDNAs. Oncogene 4, 1477–1481.
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